The GFR and Albuminuria Two-Axis System for Staging Chronic Kidney Disease

When a patient is evaluated for heart failure, clinicians look at the ejection fraction—the percentage of blood the left ventricle pumps out with each contraction. But they also look at the physical structure of the heart muscle itself. Chronic kidney disease (CKD) staging now operates on a similar dual-axis principle.

Instead of relying solely on how much blood the kidneys filter per minute, the current Kidney Disease: Improving Global Outcomes (KDIGO) framework requires a second measurement: the amount of protein leaking into the urine. This two-dimensional grid—combining glomerular filtration rate (GFR) and albuminuria—has fundamentally changed how clinicians predict which patients will progress to kidney failure and which will face severe cardiovascular events.[1][2]

The shift away from a single-number system addresses a biological reality: the kidneys can sustain significant structural damage long before their filtration capacity drops. The GFR measures the volume of fluid filtered from the renal glomerular capillaries into the Bowman's capsule per unit time. A normal estimated GFR (eGFR) is generally considered to be 90 milliliters per minute per 1.73 square meters (mL/min/1.73 m2) or higher.

Under older models, a patient with an eGFR of 95 mL/min/1.73 m2 might be told their kidney function was normal. However, if that same patient's kidneys were leaking 300 milligrams of albumin per gram of creatinine (mg/g) into their urine, the structural damage was already profound, and their risk of progression was high.[3][4]

The KDIGO framework, first introduced in 2012 and updated in 2024, formalizes this relationship into a heat map. The horizontal axis represents the eGFR, divided into six categories: G1 (90 or higher), G2 (60 to 89), G3a (45 to 59), G3b (30 to 44), G4 (15 to 29), and G5 (less than 15, indicating kidney failure).

The vertical axis represents albuminuria, divided into three categories based on the albumin-to-creatinine ratio (ACR): A1 (less than 30 mg/g, considered normal to mildly increased), A2 (30 to 299 mg/g, moderately increased), and A3 (300 mg/g or higher, severely increased).[1][2][4]

By intersecting these two variables, the KDIGO grid stratifies patients into four risk categories, color-coded from green (low risk) to yellow (moderately increased risk), orange (high risk), and red (very high risk). A patient in category G3a (eGFR 45-59) with A1 albuminuria (less than 30 mg/g) falls into the yellow zone. But a patient with the exact same eGFR of 45-59 who has A3 albuminuria (over 300 mg/g) is in the red zone. The filtration rate is identical, but the clinical reality is entirely different.[1][4]

The predictive power of this two-axis system is substantial. A systematic review published in JAMA analyzed data from over 2 million participants across multiple cohorts. The researchers found that both lower eGFR and higher albuminuria were independently associated with increased risks of all-cause mortality, cardiovascular mortality, and end-stage renal disease (ESRD). Crucially, the risks multiplied when both markers were abnormal.

For example, compared to a reference group with an eGFR of 95 and an ACR of 5, the hazard ratio for ESRD in a patient with an eGFR of 45 and an ACR of 30 was 11. But if that ACR increased to 300, the hazard ratio for ESRD jumped to 67.[3]

This multiplicative risk extends beyond the kidneys. Albuminuria is increasingly recognized as a marker of systemic endothelial dysfunction—damage to the inner lining of blood vessels throughout the body. A state-of-the-art review in Circulation highlighted that albuminuria is a potent predictor of cardiovascular events, including heart attacks and strokes, independent of traditional risk factors like blood pressure and cholesterol. The presence of albumin in the urine signals that the microvasculature is compromised, making the KDIGO grid a tool for assessing cardiovascular risk as much as renal risk.[6]

The clinical implications of the two-axis system are most evident in the management of diabetes, the leading cause of CKD globally. The American Diabetes Association's 2026 Standards of Care explicitly rely on the KDIGO grid to guide treatment.

For patients with type 2 diabetes and CKD, the guidelines recommend specific classes of medications—such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs)—based not just on the eGFR, but heavily on the presence and severity of albuminuria. These drugs have been shown to slow the progression of kidney disease and reduce cardiovascular events, but their efficacy is often most pronounced in patients with elevated albuminuria.[7]

Despite the clear evidence supporting the two-axis system, implementation remains uneven. The National Kidney Foundation notes that while eGFR is routinely reported on standard metabolic panels, albuminuria testing requires a specific urine test (the urine albumin-to-creatinine ratio, or uACR) that is frequently omitted in primary care settings. A systematic review of the global burden of CKD found that while the prevalence of decreased eGFR is well-documented, data on albuminuria prevalence is sparse in many regions, limiting the ability to accurately stage the disease at a population level.[4][8]

The American Journal of Kidney Diseases' commentary on the KDIGO guidelines emphasizes that the failure to measure albuminuria results in missed opportunities for early intervention. When clinicians rely solely on eGFR, they may not initiate renoprotective therapies until the filtration rate has already declined significantly. By the time a patient reaches stage G3 or G4, the structural damage is often irreversible. The two-axis system, when fully utilized, shifts the focus from managing late-stage failure to preventing progression in the early stages.[5]

The KDIGO 2024 update reinforced the centrality of the GFR-albuminuria grid, while also integrating new tools for risk prediction, such as the Kidney Failure Risk Equation (KFRE). The KFRE incorporates age, sex, eGFR, and uACR to provide a personalized percentage risk of progressing to kidney failure over two and five years. This evolution represents a move from categorical staging (green, yellow, orange, red) to continuous risk assessment, but the foundational axes—filtration and structural damage—remain the same.[1]